Ranbaxy sets aside $500m for manufacturing penalties
December 22, 2011Manufacturing and Production
Indian drugmaker Ranbaxy Laboratories has set aside $500 million to pay financial penalties levied by the US FDA, resulting from …
RSA makes three new appointments
December 22, 2011Business Services, Medical Communications, Sales and Marketing rsa
Life sciences recruitment firm RSA has announced three new appointments to its UK office. Dr David Jay joins RSA UK …
FDA accepts Pfizer’s arthritis pill for review
December 22, 2011Research and Development, Sales and Marketing FDA, Pfizer, tofacitinib
The FDA has accepted Pfizer’s novel arthritis pill tofacitinib for review, and could be on the US market next year. …
GSK sells off over-the-counter brands
December 22, 2011Sales and Marketing GSK, OTC
GlaxoSmithKline has offloaded a number of OTC consumer health brands in North America for £426 million in cash. Flagged up …
Department of Health slims down agency partners
December 21, 2011Medical Communications DH, Freud Communications, MEC
The Department of Health has stripped back its use of comms agencies in its public health campaigns by switching to …
AstraZeneca takes option on new diabetes candidates
December 21, 2011Sales and Marketing AstraZeneca, diabetes
AstraZeneca and Prosidion, a subsidiary of Astellas have signed a deal giving AstraZeneca an exclusive option to acquire two diabetes …
Caudex Medical makes two senior appointments
December 21, 2011Business Services, Medical Communications, Sales and Marketing Andy Bowman, Caudex Medical, Gary Burd
Andy Bowman and Gary Burd have been appointed to senior positions within the medical communications firm Caudex Medical. Bowman has …
FDA to probe Gilenya patient death
December 21, 2011Sales and Marketing FDA, Novartis, gilenya
The FDA is investigating Novartis’s new multiple sclerosis treatment Gilenya after a patient died within hours of taking the drug. …
Xarelto gains new licences in UK
December 20, 2011Sales and Marketing
Bayer’s anticoagulant pill Xarelto has gained two new lucrative licences, and is now available in the UK to prevent stroke …
AstraZeneca, Novo and Enlight sign collaborative research deal
December 20, 2011Research and Development, Sales and Marketing AstraZeneca, Enlight, Novo Nordisk
AstraZeneca and Novo Nordisk have linked up with a US biosciences firm in a bid to enhance their R&D operations. …
Pharma manufacturing news in brief
December 20, 2011Manufacturing and Production ADC Biotechnology, BioMarin, GE Healthcare, Lonza and Neptune Technologies, M+W Group
Facility news from BioMarin, Lonza and Neptune Technologies, plus plans to boost biomanufacturing capacity in the developing world and new …
Akzo Nobel warned by FDA over Mexican facility
December 20, 2011Manufacturing and Production Akza Nobel, manufacturing
Akzo Nobel has been taken to task by the US FDA for manufacturing standards at one of its active pharmaceutical …
AstraZeneca posts drug failures, takes $382m hit
December 20, 2011Research and Development, Sales and Marketing AstraZeneca, depression, ovarian cancer
AstraZeneca has taken a major blow to its late stage pipeline, with one of its key cancer drugs now being …
Brilique recommended for use by Germany’s pricing watchdog
December 19, 2011Sales and Marketing AstraZeneca, Brilique, Plavix
Germany’s new pricing committee has said that AstraZeneca’s Brilique is a cost effective treatment for patients with a certain heart …
Ex-EMA chief ran consultancy firm whilst still in office
December 19, 2011Sales and Marketing EMA, Lonngren, NDA
The former head of the European Medicines Agency Thomas Lonngren set up his own consultancy business to advise pharma whilst …
Key product launches of 2011
December 19, 2011Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing 2011, Actos, Benlysta, Brilique, Eliquis, Eylea, Incivek, Jevtana, Multaq, Victrelis, Xalkori, Yervoy, Zytiga, avastin, gilenya, key products
Avastin 2011 saw a handful of high profile drugs suffer because of new safety and efficacy concerns. Chief among these …
Vertex chief to step down; names Jeffrey Leiden as new leader
December 19, 2011Business Services, Manufacturing and Production, Research and Development, Sales and Marketing Abbott, Vertex
Vertex has named a new chief executive to succeed Matthew Emmens, who will retire early next year. He will be …
Priorclave Success at London Vet show
December 19, 2011Manufacturing and Production
During the recent London Vet Show the autoclave featured on the Southwest Medical stand R30 certainly proved a popular visitor …
University Teaching Labs Buy into Priorclaves for Better Performance
December 19, 2011Manufacturing and Production
York University is shortly taking delivery of a number of priorclaves for use in the Biology Department’s Teaching Laboratories and …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
